← All trials
NCT02568267
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2015
- Primary completion
- Oct 1, 2017
- Completion date
- Oct 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 9 / —
- Source
- AACT · pre-existing
Sponsors
- Ignyta, Inc.Lead sponsor
- Ignyta, Inc.Study director
Drugs studied
Indications studied
- Thyroid Cancer, Papillary
- Brain Neoplasms
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Head and Neck Neoplasms
- Melanoma
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Salivary Gland Neoplasms
- Sarcoma
- Colorectal Neoplasms
- Lymphoma, Large-Cell, Anaplastic
- Cholangiocarcinoma
- Neuroendocrine Tumors
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.